danaxforfree.blogg.se - Topcat trial

TOPCAT TRIAL TRIAL
TOPCAT TRIAL SERIES

* strncpy_from_unsafe: - Copy a NUL terminated string from unsafe address.

* probe_user_write(): safely attempt to write to a user-space -148,7 +147,6 long _probe_user_write(void _user *dst, const void *src, size_t size) +++ -121,7 +121,6 long _probe_kernel_write(void *dst, const void *src, size_t size) These two functions are not used by any modular code.

` (18 subsequent siblings) 19 siblings, 0 replies 54+ messages in thread 16:00 ` maccess: remove various unused weak aliases Christoph Hellwig 16:00 clean up and streamline probe_kernel_* and friends v2 Christoph 16:00 ` Christoph Hellwig * maccess: unexport probe_kernel_write and probe_user_write That avoids a number of hard to trace casts, and it will still work This version also switches to the saner copy_user as Over to this new mechanism by reusing the unsafe_* uaccess logic. Temporarily allowing access to user memory. The kernel probing without overriding the address space limit and Helpers in mm/maccess.c, and then allows architectures to implement

TOPCAT TRIAL SERIES

This series start cleaning up the safe kernel and user memory probing To: x86, Alexei Starovoitov, Daniel Borkmann, Masami Hiramatsu,Ĭc: linux-parisc, linux-um, netdev, bpf, linux-mm, linux-kernel ` (19 more replies) 0 siblings, 20 replies 54+ messages in threadįrom: Christoph Hellwig 16:00 UTC ( / raw) 16:00 ` maccess: unexport probe_kernel_write and probe_user_write Christoph Hellwig Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist - TOPCAT.Clean up and streamline probe_kernel_* and friends v2 All of help / color / mirror / Atom feed * clean up and streamline probe_kernel_* and friends v2 16:00 Christoph Hellwig Spironolactone for Heart Failure with Preserved Ejection Fraction. Heterogeneity among patients may have impacted the results as well" (2)

TOPCAT TRIAL TRIAL

The exact characterization of patients with HFpEF in the current trial is not available. It is also important to note that although historically considered a diagnosis of exclusion, recent guidelines suggest employing objective clinical and imaging criteria for HFpEF, which include protocols for excluding HFpEF. Similarly, a reduction in mortality for women is hypothesis generating and deserves further study.findings do not support a role for mineralocorticoid receptor antagonists in these patients. The reduction in CHF hospitalizations with spironolactone is hypothesis generating and deserves further study. There was also a significantly higher rate of hyperkalemia and renal failure in patients treated with spironolactone. The majority of these patients were already on an ACEI/ARB.

"results of the TOPCAT trial indicate that spironolactone is not superior to placebo in improving CV outcomes in patients with HFpEF.

study authors concluded that ".In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.".

With frequent monitoring, there were no significant differences in the incidence of serious adverse events, a serum creatinine level of 3.0 mg per deciliter (265 μmol per liter) or higher, or dialysis. 9.1% in the placebo group) but reduced hypokalemia.

treatment with spironolactone was associated with increased serum creatinine levels and a doubling of the rate of hyperkalemia (18.7%, vs.

neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone.

of the components of the primary outcome, only hospitalization for heart failure had a significantly lower incidence in the spironolactone group than in the placebo group (206 patients vs.

mean follow-up of 3.3 years, the primary outcome occurred in 320 of 1722 patients in the spironolactone group (18.6%) and 351 of 1723 patients in the placebo group (20.4%) (hazard ratio, 0.89 95% confidence interval, 0.77 to 1.04 P=0.14).

Restrictive, infiltrative, or hypertrophic cardiomyopathy.

Controlled systolic BP, defined as a target systolic BP 2.5 mg/dl.

Left ventricular EF (LVEF)>=45%, assessed within 6 months.

primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.

assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo.